This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Dividend Stocks Shoveling Cash to Shareholders

Bristol-Myers Squibb

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

$56 billion drug maker Bristol-Myers Squibb (BMY - Get Report) has had a strong year in 2011; shareholders have seen their stakes appreciate more than 25% since the first trading day of January. Now management is upping the ante, hiking the firm's quarterly dividend by 3.03% to 34 cents per share.

While that doesn't sound like much of an increase, BMY is already a perennially high-yielding stock (and one of the top-yielding drug stocks). Shares currently pay out a 4.08% yield on current share price levels.

Bristol's pharmaceutical pipeline puts it a step ahead of most of its peers. The firm treats its pipeline like any good portfolio manager, diversifying away the risks of failure though exposure to a significant number of treatments as well as partnerships with peer firms.

Like most big pharma names, however, Bristol isn't immune from the patent drop-offs that are plaguing drug developers in the next several years. The firm will need to push its late-stage pipeline along if it wants to mitigate that downside.

Financially, Bristol-Myers Squibb is in solid shape, with a deep net cash position and considerable free cash flow generation abilities. That should secure the firm's hefty dividend payout going forward.

One big bet on Bistol-Myers comes from Renaissance Technologies, which owns 3.2 million shares of the stock as of the most recently reported quarter.
2 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
AET $99.22 0.00%
AMP $82.79 0.00%
BMY $59.63 0.00%
ECL $106.17 0.00%
EQR $73.59 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs